000189284 001__ 189284
000189284 005__ 20180913062051.0
000189284 0247_ $$2doi$$a10.1111/eci.12117
000189284 022__ $$a0014-2972
000189284 02470 $$2ISI$$a000323152800011
000189284 037__ $$aARTICLE
000189284 245__ $$aPathophysiological role of the renin-angiotensin system on erectile dysfunction
000189284 260__ $$aHoboken$$bWiley-Blackwell$$c2013
000189284 269__ $$a2013
000189284 300__ $$a8
000189284 336__ $$aReviews
000189284 520__ $$aBackground The renin-angiotensin system (RAS) has been shown to play an active role within the erectile tissues. The aim of this narrative review is to summarize the literature addressing the pathophysiological role of RAS on erectile function. Additionally, we update evidence on recent findings on the role of the Ang-(1-7) and Mas receptor on the erectile function and its therapeutic potential for treating erectile dysfunction (ED). Materials and methods This narrative review is based on the material searched and obtained via MEDLINE and PubMed up to November 2012. The search terms we used are angiotensin, erectile dysfunction, renin, Mas receptor' in combination with pathophysiology, fibrosis, pathways'. Results The levels of angiotensin (Ang) II, the main component of this system, are increased in the corpus cavernosum as compared to those found in the systemic circulation. Moreover, emerging evidence indicates that an increased activity of Ang II via AT1 receptor might contribute to the development of ED, whereas the pharmacological blockage of Ang II/AT1 actions has beneficial effects on the erection. On the other hand, the heptapeptide Ang-(1-7), known as a major endogenous counter-regulator of Ang II actions, favours penile erection via the activation of Mas receptor. Conclusions Ang-(1-7) and Mas receptor pathway might be considered as a promising therapeutic target for the treatment of ED.
000189284 6531_ $$aAngiotensin II
000189284 6531_ $$aangiotensin-(1-7)
000189284 6531_ $$aerectile dysfunction
000189284 6531_ $$aMas receptor
000189284 6531_ $$arenin-angiotensin system
000189284 700__ $$aFraga-Silva, Rodrigo A.$$uEcole Polytech Fed Lausanne, Inst Bioengn, CH-1007 Lausanne, Switzerland
000189284 700__ $$aMontecucco, Fabrizio$$uUniv Hosp Geneva, Fdn Med Res, Fac Med, Div Cardiol, CH-1211 Geneva, Switzerland
000189284 700__ $$aMach, Francois$$uUniv Hosp Geneva, Fdn Med Res, Fac Med, Div Cardiol, CH-1211 Geneva, Switzerland
000189284 700__ $$aSantos, Robson A. S.
000189284 700__ $$0240635$$aStergiopulos, Nikos$$g106482$$uEcole Polytech Fed Lausanne, Inst Bioengn, CH-1007 Lausanne, Switzerland
000189284 773__ $$j43$$k9$$q978-985$$tEuropean Journal Of Clinical Investigation
000189284 909C0 $$0252351$$pLHTC$$xU11843
000189284 909CO $$ooai:infoscience.tind.io:189284$$pSTI$$preview
000189284 917Z8 $$x192494
000189284 937__ $$aEPFL-REVIEW-189284
000189284 973__ $$aEPFL$$rREVIEWED$$sPUBLISHED
000189284 980__ $$aREVIEW